You just read:

Audentes Therapeutics to Present New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy, at the 23rd International Congress of the World Muscle Society

News provided by

Audentes Therapeutics, Inc.

Sep 24, 2018, 08:00 ET